Opus Genetics, Inc. Payments to Acquire Businesses, Gross
Opus Genetics, Inc. (IRD) had Payments to Acquire Businesses, Gross of $1.57 million as of 2020-11-05, per its 10-K filed 2021-03-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesGross · last filed 2021-03-11
- 2020-11-05: Payments to Acquire Businesses, Gross $1.57M.
| Period end | Payments to Acquire Businesses, Gross |
|---|---|
| 2020-11-05 | $1.57M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |